Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 14/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.32 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9994585 | 0.84 | MGLL (0.41) | MGLLIRAK4GAAPDK2IRAK1 | |
| SCHEMBL1799985 | 0.78 | MGLL (0.34) | MGLL | |
| SCHEMBL12757786 | 0.77 | CTH (0.31) | — | |
| SCHEMBL13345964 | 0.77 | CTH (0.31) | — | |
| SCHEMBL9994588 | 0.76 | MGLL (0.40) | MGLLIRAK4GAAPDK2IRAK1 | |
| SCHEMBL13195396 | 0.75 | LMNA (0.37) | MGLL | |
| SCHEMBL1796877 | 0.75 | LMNA (0.40) | MGLL | |
| SCHEMBL23725735 | 0.74 | IRAK4 (0.42) | MGLLIRAK4IRAK1 | |
| SCHEMBL21274152 | 0.74 | IRAK4 (0.42) | MGLLIRAK4IRAK1 | |
| SCHEMBL2355265 | 0.74 | CCNE1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395551-B1 | HYDROXY ALKYL AMINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND SIMILAR DISEASES | ELAN PHARM INC (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20070299263-A1 | Hydroxy Alkyl Amines | Elan Pharmaceuticals, Inc. and Pharmacia & Upjohn Company | 2007-12-27 | — | — | US | disclosed |
| US-7144897-B2 | Hydroxy alkyl amines | Elan Oharmaceuticals, Inc. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1395551-A2 | HYDROXY ALKYL AMINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND SIMILAR DISEASES | Elan Pharmaceuticals, Inc. (US) | 2004-03-10 | — | — | EP | disclosed |
| US-20030166717-A1 | Hydroxy alkyl amines | FRESKOS JOHN (US) | 2003-09-04 | — | — | US | disclosed |
| WO-2002098849-A2 | HYDROXY ALKYL AMINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF ALZHEIMER’S DISEASE AND SIMILAR DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166717-A1 | Hydroxy alkyl amines | PSEN1, MAOA, PSEN2 | MGLL 2824/4885IRAK4 4593/4885GAA 217/4885 |
| US-20070299263-A1 | Hydroxy Alkyl Amines | MAOA, PSEN2, PSEN1 | MGLL 2173/4885IRAK4 4717/4885GAA 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.